매년 심혈관 질환(CVD)으로 인한 사망자수는 약 1,800만 명, 암으로 인한 총 사망자 수를 상회1,2 CVD 발생 위험을 높이는 유전적 요인인 높은Lp(a)는 전 세계 5명 중 1명에게 영향을 미치고 있음에도 검사율은 매우 낮은 수준에 그쳐3 아시아 태평양 및 중동 지역에서 실시한 새로운 설문조사에서 답변자의 66%가 정기적으로 심장 검사를 받지 않으며, 거의 절반이 심장 질환과의 유전적 연관성을 인식하지 못하고 있는 것으로 나타나 전문가들은 심혈관 전략에 있어 Lp(a)에 중요성을 부각하고, 인식 격차를 해소하며, 검사와 치료에 대한 형평성 있는 접근을 제공할 것을 촉구 싱가포르, 2025년 9월 24일 -- 매년 심혈관 질환(CVD)으로 인한 사망자수는 약 1,800만 명에 이르며, 이는 모든 암으로 인한 사망자 수를 합친 것보다 많다. 그럼에도 불구하고, 최근까지도 잘 알려지지 않은 유전적 위험 요인으로 높은 Lp(a)가 꼽히고 있다.1,2 Lp(a)는 "작지만 치명적인 a"로 불리며, 전 세계 인구의 5명 중 1명에게 영향을 미치는 것으로 알려져 있다. 다만, Lp(a) 검사율은
런던, 2025년 9월 24일 -- 지난 1년간 전 세계 자선단체가 제공하는 서비스에 대한 수요가 증가한 것으로 영국 자선지원재단(Charities Aid Foundation, 이하 CAF)이 새로 발표한 글로벌 연구 보고서를 통해 나타났다. 보고서 제목은 '세계 기부 보고서: 자선단체 인사이트(World Giving Report: Charity Insights)'로, 전 세계 27개국 3000명 이상의 자선단체 리더들을 대상으로 실시한 글로벌 동향과 과제에 대한 조사 결과가 담겨있다. 뉴욕 유엔 총회 부대행사에서 발표된 본 보고서는 올해 초 발간된 '세계 기부 보고서: 기부자 인사이트(World Giving Report: Donor Insights)'에 이은 후속 보고서다. 조사 대상 자선단체 리더 5명 중 4명 가까이(78%)는 지난해 서비스 수요가 증가했다고 답했으며, 약 절반(47%)은 이 증가세가 상당히 컸다고 밝혔다. 리더들은 이러한 수요 증가의 원인으로 심화하는 경제적 어려움, 고조되는 사회적 위기, 공공 서비스 축소 분위기를 꼽았다. 특히 저소득 국가(84%) 자선단체 리더들이 서비스 수
[ 메디채널 김갑성 기자 ] Global developers unite at inaugural event, leveraging Tencent Cloud's AI tools to drive social innovation in biodiversity and mental health SHENZHEN, China, Sept. 24, 2025 -- The inaugural Tencent Cloud Hackathon Global Roadshow Day, held alongside the 2025 Tencent Global Digital Ecosystem Summit, concluded successfully in Shenzhen. Over 48 hours, 17 teams comprising 46 developers collaborated intensely to build 17 innovative "AI for Social Good" projects, showcasing how technology can drive meaningful social impact. In partnership with Tence
TOKYO, Sept. 24, 2025 -- Intent Exchange, Inc. ("Intent Exchange"), NEC Corporation ("NEC"), and NTT DATA Japan Corporation ("NTT DATA") today announced the pilot deployment of Unmanned Aircraft System Traffic Management ("UTM") system at Expo 2025 Osaka, Kansai, Japan ("the Expo"). The System is designed to provide unified monitoring of drone and advanced air mobility ("AAM") operations within and around the Expo site. The pilot operation will be conducted from August 16 to October 13, 2025, with the aim of validating usability from
YONGIN, South Korea, Sept. 24, 2025 -- GCCL (Global Clinical Central Lab), a South Korea-based leading provider of clinical trial sample analysis, and Frontage Laboratories, Inc., a USA based full-service contract research organization (CRO), announced on September 23 that they had signed a strategic Memorandum of Understanding (MOU) pursuant to which they intend to explore ways to strengthen their presence in the global clinical trial market. In signing the MOU, GCCL and Frontage intend to consider opportunities to leverage the complementary services and networks
LONDON, Sept. 24, 2025 -- Charities around the world say that demand for their organisation's services has increased over the last year, according to new global research by the Charities Aid Foundation (CAF). CAF's World Giving Report: Charity Insights explores the global trends and challenges for over 3,000 charity leaders in 27 countries. The report is being launched at a side event at the United Nations General Assembly in New York and follows the publication of World Giving Report: Donor Insights earlier this year. Nearly four in five (78%) of charities surv
HEERENVEEN, Netherlands, Sept. 24, 2025 -- Titomic Limited (ASX: TTT), a global leader in Titomic Kinetic Fusion™, a cold spray additive manufacturing technology, is pleased to announce the grand opening of its new Titomic Europe facility in Heerenveen, Netherlands. This milestone marks a significant expansion of the company's European operations, underscoring its commitment to innovation and advanced manufacturing. The new Heerenveen facility is five times the size of Titomic's other Europe location in Akkrum, offering a state-of-the-art environment designed to accelerate grow
BEIJING, Sept. 24, 2025 -- The 2025 Shanghai pioneering industries conference, hosted by Guotai Haitong Securities, was recently held in east China's Shanghai. The event also featured the 14th pharmaceutical CEO forum and the 5th artificial intelligence (AI) conference. The event brought together nearly 100 industry leaders, representatives from almost 200 listed companies and around 1,000 investors to explore cutting-edge trends and cross-sector opportunities in biopharmaceuticals and technology. Discussions centered on innovative drug research and development, advances in medi
NORWALK, Conn., Sept. 24, 2025 -- Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and development collaboration with Eli Lilly and Company ("Lilly") focused on advancing innovative gene therapies for Type 2 diabetes and obesity. This partnership underscores the promise of Remedium's proprietary Prometheus™ platform and the company's leadership in developing long-acting, adjustable-dose therapeutics for major unmet medical needs. This approach aims to replace
BOSTON, Sept. 24, 2025 -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, today announced powerful new capabilities in its Orchestration Platform for Universal Solutions (OPUS) designed to unlock unprecedented productivity. These enhancements enable finance, commercial, and IT teams to radically improve agility and productivity while reducing costs through agentic orchestration of their end-to-end supply chain. The new capabilities, introduced across OPUS, Multienterprise Information Network Tower (MINT), Process Orc